FDA OKs Tygacil

The FDA has approved Wyeth Pharmaceuticals' antibiotic Tygacil to treat bacterial infections. The move gives hospitals another weapon in the war against new and disturbingly durable infections, including methicillin-resistant staph aureus, or MRSA, which has spread beyond hospitals and into the community. The new antibiotic is intended to combat a broad range of bacteria. Side effects include nausea and vomiting.

- read this article from the AP for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.